Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
In BriefThis Month in JNM

This Month in JNM

Journal of Nuclear Medicine March 2019, 60 (3) 6A;
  • Article
  • Info & Metrics
  • PDF
Loading

Discussions with leaders: JNM editor-in-chief Johannes Czernin continues a series of interviews with leaders in nuclear and molecular imaging and therapy with a conversation with Simon Cherry.

Page 295

Human total-body PET: Badawi and colleagues present the first human imaging studies on the EXPLORER scanner, using a range of different protocols that provide foundational evidence for future trials to evaluate improvements and innovations facilitated by total-body PET imaging.

Page 299

H&N perineural spread imaging: Lee and colleagues provide an educational overview of tumor growth along large nerves and the role of 18F-FDG PET in assessment of perineural spread in head and neck cancer.

Page 304

11C-MET PET in DIPG: Tinkle and colleagues investigate uptake of 11C-methionine in pediatric patients with newly diagnosed diffuse intrinsic pontine glioma and explore associations between PET metrics, conventional MR imaging, and survival.

Page 312

Ki estimates from static PET: Doot summarizes previous reports on changes in primary breast cancer tumor and SUVs from serial 18F-FDG PET scans and patient outcomes and previews a related article in this issue of JNM.

Page 320

18F-Fluoride Ki, SUV, and bone metastases: Azad and colleagues determine whether PET/CT measurement of changes in 18F-fluoride metabolic flux to bone mineral, compared with SUVmax and SUVmean, can improve response assessment of bone metastases in breast cancer.

Page 322

18F-FDG PET response criteria in NSCLC: Turgeon and colleagues compare survival outcomes according to 4 international criteria for defining response with 18F-FDG PET after curative-intent chemoradiation for non–small cell lung cancer.

Page 328

Ipilimumab response using imPERCIST5: Ito and colleagues assess associations between tumor response on 18F-FDG PET/CT and prognosis in patients with metastatic malignant melanoma treated with ipilimumab.

Page 335

Scintigraphy and TIRADS: Schenke and colleagues look at the value of the addition of thyroid scintigraphy to the Thyroid Imaging Reporting and Data System to avoid unnecessary fine-needle biopsies and thyroid surgeries.

Page 342

HK2 expression in multiple myeloma imaging: Kircher and colleagues explore reasons for PET false-negativity with both 18F-FDG and 11C-methionine in patients with relapsed or refractory biopsy-proven and active multiple myeloma.

Page 348

PET and EGFR-targeted therapy: Burley and colleagues investigate human epidermal growth factor receptor 1–specific radioligands for measurement of EGFR expression across the entire tumor burden in head and neck cancer and for monitoring of cetuximab-mediated changes in receptor expression.

Page 353

18F-PSMA-1007 PET/CT in PCa restaging: Giesel and colleagues evaluate the diagnostic efficacy of 18F-PSMA-1007 PET/CT for biochemical recurrence after radical prostatectomy in 251 patients.

Page 362

Somatostatin PET in PPGLs: Han and colleagues report on a systematic review and metaanalysis of the performance of 68Ga-DOTA–conjugated somatostatin receptor–targeting peptide PET in detection of pheochromocytomas and paragangliomas.

Page 369

PRRT in G3 neuroendocrine neoplasms: Zhang and colleagues analyze long-term outcomes, efficacy, and safety of peptide-receptor radionuclide therapy in patients with somatostatin receptor–expressing grade 3 neuroendocrine neoplasms.

Page 377

68Ga-FAPI PET/CT: Giesel and colleagues detail tissue biodistribution and preliminary dosimetry of DOTA-containing fibroblast activation protein–targeting agents in patients with various cancers.

Page 386

177Lu-Labeled minigastrin: Sauter and colleagues investigate whether a chemically stabilized analog performs better than reference analogs in cholecystokinin-2 receptor targeting in metastatic medullary thyroid cancer in basic, translational, and first-in-human studies.

Page 393

111In-DOTA-5D3 SPECT for PSMA: Banerjee and colleagues characterize this new high-affinity murine monoclonal antibody targeting prostate-specific membrane antigen using SPECT/CT imaging, tissue biodistribution studies, and dosimetry.

Page 400

PET and stable CAD management: Di Carli and Hachamovitch provide perspective on ischemia-guided approaches in management of stable coronary artery disease and preview an article in this issue of JNM on PET-assessed quantitative flow measurements.

Page 407

Cardiac PET and coronary revascularization: Gould and colleagues research the threshold of quantitative myocardial perfusion severity for association with reduced death, myocardial infarction, or stroke after revascularization within 90 days after PET.

Page 410

Clinical translation of NIR tracers: Linssen and colleagues describe their development and production process for near-infrared agents cetuximab-800CW and trastuzumab-800CW and provide a roadmap for developing monoclonal antibody tracers into regulatory-compliant drug products.

Page 418

Photonuclear production of 15O: Queern and colleagues report on a novel and economical approach to production of 15O for PET applications using an electron linear accelerator.

Page 424

DIVIDE pseudo-CT for pelvis PET/MR AC: Torrado-Carvajal and colleagues describe a deep-learning network for synthesis of pelvis pseudo-CT maps based on standard Dixon volumetric-interpolated breath-hold images currently acquired for attenuation correction in some commercial scanners.

Page 429

  • © 2019 by the Society of Nuclear Medicine and Molecular Imaging.
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 60 (3)
Journal of Nuclear Medicine
Vol. 60, Issue 3
March 1, 2019
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
This Month in JNM
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
This Month in JNM
Journal of Nuclear Medicine Mar 2019, 60 (3) 6A;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
This Month in JNM
Journal of Nuclear Medicine Mar 2019, 60 (3) 6A;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • Practical Methods for Estimating Metabolic Flux (Ki) to Assess Response to Therapy via Static PET Scans
  • First Human Imaging Studies with the EXPLORER Total-Body PET Scanner*
  • Hexokinase-2 Expression in 11C-Methionine–Positive, 18F-FDG–Negative Multiple Myeloma
  • Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients
  • Roadmap for the Development and Clinical Translation of Optical Tracers Cetuximab-800CW and Trastuzumab-800CW
  • Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog 177Lu-DOTA-PP-F11N: Does the Use of Protease Inhibitors Further Improve In Vivo Distribution?
  • What 18F-FDG PET Response-Assessment Method Best Predicts Survival After Curative-Intent Chemoradiation in Non–Small Cell Lung Cancer: EORTC, PERCIST, Peter Mac Criteria, or Deauville Criteria?
  • Quantitative Coronary Flow Capacity for Risk Stratification and Clinical Decision Making: Is It Ready for Prime Time?
  • Performance of 68Ga-DOTA–Conjugated Somatostatin Receptor–Targeting Peptide PET in Detection of Pheochromocytoma and Paraganglioma: A Systematic Review and Metaanalysis
  • Evaluation of 11C-Methionine PET and Anatomic MRI Associations in Diffuse Intrinsic Pontine Glioma
  • Regional, Artery-Specific Thresholds of Quantitative Myocardial Perfusion by PET Associated with Reduced Myocardial Infarction and Death After Revascularization in Stable Coronary Artery Disease
  • Discussions with Leaders: A Conversation between Simon Cherry and Johannes Czernin
  • 68Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers
  • Detection Efficacy of 18F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy
  • Evaluation of 111In-DOTA-5D3, a Surrogate SPECT Imaging Agent for Radioimmunotherapy of Prostate-Specific Membrane Antigen
  • Dixon-VIBE Deep Learning (DIVIDE) Pseudo-CT Synthesis for Pelvis PET/MR Attenuation Correction
  • Is Response Assessment of Breast Cancer Bone Metastases Better with Measurement of 18F-Fluoride Metabolic Flux Than with Measurement of 18F-Fluoride PET/CT SUV?
  • 18F-FDG PET/CT for Monitoring of Ipilimumab Therapy in Patients with Metastatic Melanoma
  • Affibody-Based PET Imaging to Guide EGFR-Targeted Cancer Therapy in Head and Neck Squamous Cell Cancer Models
  • Risk Stratification of Thyroid Nodules Using the Thyroid Imaging Reporting and Data System (TIRADS): The Omission of Thyroid Scintigraphy Increases the Rate of Falsely Suspected Lesions
  • Production of 15O for Medical Applications via the 16O(γ,n)15O Reaction
  • An Imager’s Guide to Perineural Tumor Spread in Head and Neck Cancers: Radiologic Footprints on 18F-FDG PET, with CT and MRI Correlates
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • This Month in JNM
  • This Month in JNM
  • This Month in JNM
Show more This Month in JNM

Similar Articles

SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire